Nucelion Therapeutics and Pandorum Technologies partner on ophthalmology projects

Hyderabad-based Nucelion Therapeutics and Bengaluru's Pandorum Technologies have partnered to advance two PRIP-backed ophthalmology projects targeting advanced keratopathy and wet age-related macular degeneration. The projects have a combined planned outlay of Rs. 16.97 crore, including up to Rs. 8 crore in PRIP funding

Hyderabad: Hyderabad-based Nucelion Therapeutics, a subsidiary of Bharat Biotech, and Bengaluru’s Pandorum Technologies have announced a manufacturing partnership to advance two Promotion of Research and Innovation in Pharma-MedTech (PRIP)-backed ophthalmology projects targeting advanced keratopathy and wet age-related macular degeneration (wet AMD), a press release said.

The collaboration combines Pandorum’s designer-exosome platform, focusing on cell-free regenerative medicines that address inflammation, fibrosis, and vascular pathology, with Nucelion’s expertise in Good Manufacturing Practice (GMP) process development and manufacturing.

---

The initiative aims to support clinical studies both in India and internationally. The projects feature a combined planned outlay of Rs 16.97 crore, which includes up to Rs 8 crore in funding under the PRIP scheme.

Dr. Raghu Malapaka, Chief Business Officer for Nucelion said that it is important to translate product requirements into reproducible processes with built-in quality.

Dr. Tuhin Bhowmick, Co-founder and CEO of Pandorum, said that the partnership connects their designer-exosome platform to rigorous manufacturing capabilities under the ‘Innovate and Make in India, for the World’ vision.